DB06464ExperimentalVaccines
IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity. It was last known to be in phase III...
- Primary indication
- Investigated for use/treatment in rheumatoid arthritis.Curator reviewed
- Code names
- IR-501
Which companies are running trials of IR501, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account